Navigation Links
Anti-Fibrotic Data from Amira Pharmaceuticals' LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology

SAN DIEGO, May 6 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.  

The LPA1 receptor is part of the Phosphatidic Acid/ Lysophosphatidylcholine pathway and has recently been implicated for having a role in lung, kidney and skin fibrosis.  In particular, activation of the LPA1 receptor may promote fibrosis in Idiopathic Pulmonary Fibrosis (IPF), a lung disease for which there are currently no effective treatments available.

"The data in this publication demonstrate the potential of a high affinity, oral antagonist of the LPA1 receptor in diseases associated with fibrosis, edema and inflammation," said James Swaney, Ph.D., Senior Scientist at Amira and the senior author of the paper.   "Importantly, our proof of concept compound, AM966, demonstrates superior efficacy in a preclinical model when compared to other anti-inflammatory and/or anti-fibrotic agents including dexamethasone and pirfenidone.  We feel that these data pave the way for novel, 'first in class' molecules to target IPF and other fibrotic diseases via blockade of the LPA1 receptor."

Bob Baltera, Chief Executive Officer of Amira, added, "We are focused on developing LPA1 antagonists in fibrotic diseases.  Many of the potential indications address specialty care markets and give Amira the opportunity to bring a therapeutic product through to commercialization.  Grievous diseases such as IPF desperately need new therapies and the team at Amira is working hard to see these opportunities into the clinic as soon as possible."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease.  Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.  For more information, visit

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
2. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
3. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
4. ADVENTRX Pharmaceuticals Announces Closing of Financing
5. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
6. Trading Halted Today in Questcor Pharmaceuticals Common Stock
7. HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals
8. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
9. Alexza Pharmaceuticals Files Shelf Registration Statement
10. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
11. Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
Post Your Comments:
(Date:11/25/2015)... N.C. , Nov. 25, 2015 ... the planned investment of at least $15.8  Million ... Wilmington, NC . The expansion ... capacity to meet the growing demands of the ... site expansion will provide up to ...
(Date:11/25/2015)... , Nov. 25, 2015  Henry Schein, Inc., the ... to office-based dental, medical and animal health practitioners, will ... the Henry Schein ConnectDental® Pavilion , which brings ... of open solutions designed to help any practice or ... here for a schedule of experts appearing at ...
(Date:11/25/2015)... 25, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to ... Annual Piper Jaffray Healthcare Conference. th ... Palace Hotel in New York ... Mr. Schuh will be available for one-on-one meetings during ...
Breaking Medicine Technology:
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed ... 1-1 ). More than 3.7 billion people under the age of 50 – or ... to WHO's first global estimates of HSV-1 infection . , "The data shocks us ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):